BioSpace News Archive

Black Diamond Therapeutics, Inc. announced the dosing of the first patient in the Phase 1 study evaluating BDTX-1535, a MasterKey inhibitor of epidermal growth factor receptor for the treatment of both non-small cell lung cancer and glioblastoma derived from Black Diamond’s MAP discovery engine.

Trevena, Inc. announced receipt of the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund.

Beyond Air, Inc. announced that the Company is scheduled to present new data at three upcoming medical conferences.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, announced the hiring of D. Taylor Ocasio as the Company’s new General Counsel.

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

OncotelicTherapeutics, Inc. announced financial results for the full year ended December 31, 2021 as compared to the full year ended December 31, 2020, an update on its product and therapeutic development initiatives and other corporate updates.

Natus Medical Incorporated announced that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed, a leading investment firm focused exclusively on the healthcare industry for approximately $1.2 billion.

Merck announced that Health Canada has granted approval for KEYTRUDA®, Merck’s anti-PD-1 therapy, as a treatment for adult patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery annual meeting, which will take place from April 22-26, 2022 in Washington, D.C.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, announced Aaron Osborne, MBBS, was appointed Chief Medical Officer and Chief Development Officer.